| Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy E Perez-Ruiz, L Minute, I Otano, M Alvarez, MC Ochoa, V Belsue, ... Nature 569 (7756), 428-432, 2019 | 381 | 2019 |
| Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients N Karachaliou, M Gonzalez-Cao, G Crespo, A Drozdowskyj, E Aldeguer, ... Therapeutic advances in medical oncology 10, 1758834017749748, 2018 | 254 | 2018 |
| Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells MC Ochoa, L Minute, I Rodriguez, S Garasa, E Perez‐Ruiz, S Inogés, ... Immunology and cell biology 95 (4), 347-355, 2017 | 223 | 2017 |
| Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies E Pérez-Ruiz, I Melero, J Kopecka, AB Sarmento-Ribeiro, ... Drug Resistance Updates 53, 100718, 2020 | 141 | 2020 |
| Bcl-2 inhibition to overcome resistance to chemo-and immunotherapy M García-Aranda, E Pérez-Ruiz, M Redondo International journal of molecular sciences 19 (12), 3950, 2018 | 128 | 2018 |
| Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types L Paré, T Pascual, E Seguí, C Teixidó, M Gonzalez-Cao, P Galván, ... Annals of Oncology 29 (10), 2121-2128, 2018 | 88 | 2018 |
| Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer A Sánchez-Muñoz, C Mendiola, E Pérez-Ruiz, CA Rodríguez-Sánchez, ... Oncology 79 (1-2), 98-104, 2010 | 56 | 2010 |
| Maintenance treatment in metastatic breast cancer A Sanchez-Munoz, E Perez-Ruiz, N Ribelles, A Marquez, E Alba Expert review of anticancer therapy 8 (12), 1907-1912, 2008 | 55 | 2008 |
| Targeted therapy of metastatic breast cancer A Sánchez-Muñoz, E Pérez-Ruiz, B Jiménez, N Ribelles, A Márquez, ... Clinical and Translational Oncology 11, 643-650, 2009 | 50 | 2009 |
| The role and prognostic value of apoptosis in colorectal carcinoma J Alcaide, R Funez, A Rueda, E Perez-Ruiz, T Pereda, I Rodrigo, ... BMC clinical pathology 13, 1-7, 2013 | 45 | 2013 |
| Clinical and sociodemographic factors that may influence the resilience of women surviving breast cancer: cross-sectional study M Padilla-Ruiz, C Ruiz-Román, E Pérez-Ruiz, A Rueda, M Redondo, ... Supportive Care in Cancer 27, 1279-1286, 2019 | 44 | 2019 |
| Anti-CD137 and PD-1/PD-L1 antibodies en route toward clinical synergy E Pérez-Ruiz, I Etxeberria, ME Rodriguez-Ruiz, I Melero Clinical Cancer Research 23 (18), 5326-5328, 2017 | 41 | 2017 |
| Tipifarnib in recurrent, metastatic HRAS‐mutant salivary gland cancer GJ Hanna, JP Guenette, NG Chau, CM Sayehli, C Wilhelm, R Metcalf, ... Cancer 126 (17), 3972-3981, 2020 | 39 | 2020 |
| Impact of epidermal growth factor receptor expression on disease-free survival and rate of pelvic relapse in patients with advanced cancer of the cervix treated with … J Pérez-Regadera, A Sánchez-Muñoz, J De-la-Cruz, C Ballestín, D Lora, ... American Journal of Clinical Oncology 34 (4), 395-400, 2011 | 33 | 2011 |
| SEOM clinical guideline for the management of cutaneous melanoma (2020) M Majem, JL Manzano, I Marquez-Rodas, K Mujika, E Muñoz-Couselo, ... Clinical and Translational Oncology 23, 948-960, 2021 | 32 | 2021 |
| Anti-angiogenic treatment (sunitinib) for disseminated malignant haemangiopericytoma: a case study and review of the literature M Delgado, E Pérez-Ruiz, J Alcalde, D Perez, R Villatoro, A Rueda Case Reports in Oncology 4 (1), 55-59, 2011 | 32 | 2011 |
| Epidemiological characteristics of a Spanish cohort of patients diagnosed with squamous cell carcinoma of head and neck: distribution of risk factors by tumor location R Seijas-Tamayo, J Fernández-Mateos, JC Adansa Klain, R Mesía, ... Clinical and Translational Oncology 18, 1114-1122, 2016 | 31 | 2016 |
| Response to paclitaxel in a radiotherapy-induced breast angiosarcoma E Perez-Ruiz, N Ribelles, A Sanchez-Muñoz, A Roman, A Marquez Acta Oncologica 48 (7), 1078-1079, 2009 | 31 | 2009 |
| Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells MC Ochoa, E Perez-Ruiz, L Minute, C Oñate, G Perez, I Rodriguez, ... Oncoimmunology 8 (7), e1599636, 2019 | 30 | 2019 |
| Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15 MC Ochoa, L Minute, A López, E Pérez-Ruiz, C Gomar, M Vasquez, ... Oncoimmunology 7 (2), e1393597, 2018 | 28 | 2018 |
